![Morphic Holding, Inc. logo](/logos/MORF.webp)
Morphic Holding, Inc.
NASDAQ:MORF
Overview | Financials
Company Name | Morphic Holding, Inc. |
Symbol | MORF |
Currency | USD |
Price | 56.99 |
Market Cap | 2,862,305,653 |
Dividend Yield | 0% |
52-week-range | 19.345 - 57 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Praveen P. Tipirneni M.D. |
Website | https://www.morphictx.com |
An error occurred while fetching data.
About Morphic Holding, Inc.
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD